Where Will Recursion Pharmaceuticals Be in 5 Years?

If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...
KTLA

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...
Nasdaq

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to ...
Benzinga.com

Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On?

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower in Wednesday’s after-hours session after the company announced a proposed offering of its common stock. What Happened: After the ...